Evidence map›Paper›PMID 26214138›Full record

ArticleBone marrow transplantation2015

Predicting survival using clinical risk scores and non-HLA immunogenetics.

Y Balavarca, K Pearce, J Norden, M Collin, G Jackson, E Holler, R Dressel, H-J Kolb, H Greinix, G Socie and 9 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 5 countries.

Y BalavarcaDepartment of Genetic Epidemiology, University Medical Center, Göttingen, Germany.
K PearceDepartment of Haematological Sciences, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK.
J NordenDepartment of Haematological Sciences, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK.
M CollinDepartment of Haematological Sciences, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK.
G JacksonNorthern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
E HollerDepartment of Hematology and Oncology, University of Regensburg, Regensburg, Germany.
R DresselDepartment of Cellular and Molecular Immunology, University Medical Center, Göttingen, Germany.
H-J KolbDepartment of Haematology and Oncology, Klinikum Grosshadern, Medical Klinik III, Munich, Germany.
H GreinixDepartment of Haematology, Division of Haematology, Medical University of Graz, Graz, Austria.
G SocieDepartment of Haematology, Immunology and Oncology, AP-HP, Saint Louis Hospital, Hematology Transplantation, Paris, France.
A ToubertDepartement d'Immunologie, Université Paris Diderot, INSERM UMRS-940, AP-HP, Paris, France.
V RochaDepartment of Bone Marrow Transplantation, EUROCORD, St Louis Hospital, Paris, France.
E GluckmanDepartment of Bone Marrow Transplantation, EUROCORD, St Louis Hospital, Paris, France.
I HromadnikovaDepartment of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
P SedlacekDepartment of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
D WolffDepartment of Hematology and Oncology, University of Regensburg, Regensburg, Germany.
U HoltickDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
A DickinsonDepartment of Haematological Sciences, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK.
H BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Göttingen, Germany.
Newcastle University · GBCharles University · CZUniversitätsmedizin Göttingen · DEUniversity of Regensburg · DEHôpital Saint-Louis · FRMedical University of Graz · ATNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversité Paris Cité · FRUniversity of Cologne · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single-nucleotide polymorphisms (SNPs) on subgroups of patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) revealed an association with transplant outcome. This study further evaluated the association of non-HLA polymorphisms with overall survival in a cohort of 762 HSCT patients using data on 26 polymorphisms in 16 non-HLA genes. When viewed in addition to an already established clinical risk score (EBMT-score), three polymorphisms: rs8177374 in the gene for MyD88-adapter-like (MAL; P=0.026), rs9340799 in the oestrogen receptor gene (ESR; P=0.003) and rs1800795 in interleukin-6 (IL-6; P=0.007) were found to be associated with reduced overall survival, whereas the haplo-genotype (ACC/ACC) in IL-10 was protective (P=0.02). The addition of these non-HLA polymorphisms in a Cox regression model alongside the EBMT-score improved discrimination between risk groups and increased the level of prediction compared with the EBMT-score alone (gain in prediction capability for EBMT-genetic-score 10.8%). Results also demonstrated how changes in clinical practice through time have altered the effects of non-HLA analysis. The study illustrates the significance of non-HLA genotyping prior to HSCT and the importance of further investigation into non-HLA gene polymorphisms in risk prediction.

Indexed as

Polymorphism, Single NucleotideAdolescentAdultAgedAllograftsCause of DeathChildEstrogen Receptor alphaFemaleFollow-Up StudiesGenotypeGraft vs Host DiseaseHaplotypesHematologic NeoplasmsHematopoietic Stem Cell TransplantationHistocompatibilityESR1 protein, humanEstrogen Receptor alphaIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6Membrane GlycoproteinsReceptors, Interleukin-1TIRAP protein, human

Identifiers

PMID26214138
OpenAlexW1484181788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.